Jeevan Scientific Technology Limited (JSTL) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.6B
Fair value as of: Jul 5, 2026
From 14 valuation models · updated today
Share price +3.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹33.91 – ₹89.43 · fair‑value band ₹7.37 – ₹12.28 · the ₹80.08 price screens above the ₹9.82 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jeevan Scientific Technology Limited (JSTL) currently trades at ₹80.08, while our model-based Fair Value estimate is ₹9.82 — implying the stock looks roughly 87.7% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Jeevan Scientific Technology Limited generated revenue of ₹615M at a net margin of 1.9%. Revenue grew 111.6% year over year. It earns a return on equity of 1.7%. Net debt stands at ₹76.5M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹7.37 (bear case) to ₹12.28 (bull case); at ₹80.08, the current price sits above that range. The share trades about 15% below its 52-week high and 144% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside — at -88%, JSTL screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and bio-statistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, drug safety, clinical data management, biostatistics and statistical programming, and quality assurance; and pharmacovigilance services, including ICSR management, aggregate safety reports, risk management plan, signal detection, medical information call center, and other integrated services. It also exports its products. The company was formerly known as Jeevan Softech Limited and changed its name to Jeevan Scientific Technology Limited in March 2011. The company was incorporated in 1999 and is based in Hyderabad, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jeevan Scientific Technology Limited reported revenue of ₹615M in FY2025 versus ₹1.5T in FY2021, a compound −85.7%/yr. Reported net income was ₹11.5M in FY2025, compounding −91.4%/yr from FY2021.
Is JSTL fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
| Hinge Health, Inc HNGE | $62.98 | $78.43 | +25% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
| 10x Genomics, Inc TXG | $31.04 | $20.68 | -33% |
| XtalPi Holdings 2228 | HK$7.48 | HK$1.03 | -86% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jeevan Scientific Technology Limited (JSTL) undervalued?
What is the fair value of JSTL?
What is the quality score of JSTL?
What is the revenue of Jeevan Scientific Technology Limited (JSTL)?
What is the net profit margin of JSTL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.